Compass Pathways announced that its investigational psilocybin treatment has successfully met its primary endpoint in a Phase ...
Compass Pathways has reported another phase 3 win for its psilocybin therapy in treatment-resistant depression, sending the ...
Treatment-Resistant Depression (TRD) stands as one of the most stubborn and costly challenges in modern healthcare. For the ...
Compass Pathways said on Tuesday its psilocybin-based therapy eased depression symptoms in a late-stage trial, sending the ...
Compass Pathways on Tuesday disclosed results from two Phase 3 studies that support a potential approval of its psilocybin treatment for severe depression, but more detailed data are needed to ...
Compass Pathways hopes to submit an NDA in Q4 leading up to potential approval.
Evidence of durability of psilocybin-based COMP360 is a key point for the FDA, according to Compass Pathways Chief Medical ...
Compass Pathways is rated a Hold due to high risk, funding needs, and the need for further data before reassessing the thesis. Read more on CMPS stock here.
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the successful achievement of the primary endpoint ...
Compass Pathways (CMPS) stock jumps as the company says psychedelic drug COMP360 hit late-stage trial endpoint in ...
2don MSN
Analysts Bullish on COMPASS Pathways plc (CMPS) Following Psychedelics Symposium and Model Updates
COMPASS Pathways plc (NASDAQ:CMPS) is among the 7 Most Promising Psychedelic Stocks According to Hedge Funds. COMPASS ...
Clinical Trials Arena on MSN
Compass stock heads north on psychedelic’s Phase III TRD success
Compass will now seek approval for COMP360, which could become the first classic psychedelic to gain the FDA’s blessing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results